meglumine and Vomiting

meglumine has been researched along with Vomiting in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (12.50)18.2507
2000's1 (12.50)29.6817
2010's6 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
AlObaidy, M; Altun, E; Burke, LM; Jeon, YH; Ramalho, M; Semelka, RC; Shin, KS; Stallings, CG1
Ando, Y; Hayashi, T; Imaizumi, K; Isaji, A; Ito, K; Kawada, K; Matsuda, H; Mine, N; Miyamoto, A; Naito, K; Nakanishi, T; Okada, T; Oya, M; Sakurai, K; Shibata, T; Suzuki, E; Takahashi, H; Uyama, I; Yamada, S1
Christensen, RE; Dillman, JR; Lai, ME; Mollard, BJ; Phan, T; Smith, EA1
Bleicher, AG; Kanal, E1
Durmus, T; Hamm, B; Heine, O; Maurer, M; Wagner, M; Wolf, M1
Castillo, M; Hernandes, Mde A; Semelka, RC; Stallings, CG1
Esfandiarpour, I; Farajzadeh, S; Fathabadi, EA; Heshmatkhah, A; Rahnama, Z1
Corzo, JE; de la Rosa, R; Delgado, J; González-Moreno, MP; Leal, M; Lissen, E; Macías, J; Pineda, JA; Sánchez-Quijano, A1

Trials

3 trial(s) available for meglumine and Vomiting

ArticleYear
Inter- and intra-individual comparative study of two gadolinium-based agents: A pilot study.
    Abdominal imaging, 2015, Volume: 40, Issue:4

    Topics: Aorta; Contrast Media; Double-Blind Method; Feasibility Studies; Female; Humans; Image Enhancement; Imaging, Three-Dimensional; Liver; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Observer Variation; Organometallic Compounds; Pancreas; Pilot Projects; Reproducibility of Results; Sensitivity and Specificity; Vomiting

2015
Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016, Volume: 24, Issue:2

    Topics: Aged; Antiemetics; Aprepitant; Cisplatin; Esophageal Neoplasms; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Meglumine; Middle Aged; Morpholines; Nausea; Risk Factors; Stomach Neoplasms; Surveys and Questionnaires; Treatment Outcome; Vomiting

2016
Objective evaluation of acute adverse events and image quality of gadolinium-based contrast agents (gadobutrol and gadobenate dimeglumine) by blinded evaluation. Pilot study.
    Magnetic resonance imaging, 2013, Volume: 31, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child, Preschool; Contrast Media; Drug Eruptions; Female; Humans; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Organometallic Compounds; Pilot Projects; Reproducibility of Results; Sensitivity and Specificity; Single-Blind Method; Vomiting; Young Adult

2013

Other Studies

5 other study(ies) available for meglumine and Vomiting

ArticleYear
MR enterography under the age of 10 years: a single institutional experience.
    Pediatric radiology, 2016, Volume: 46, Issue:1

    Topics: Administration, Oral; Child; Child, Preschool; Contrast Media; Female; Humans; Infant; Infant, Newborn; Inflammatory Bowel Diseases; Magnetic Resonance Imaging; Male; Meglumine; Michigan; Nausea; Organometallic Compounds; Prevalence; Retrospective Studies; Risk Factors; Vomiting

2016
Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine.
    AJR. American journal of roentgenology, 2008, Volume: 191, Issue:6

    Topics: Contrast Media; Dyspnea; Humans; Magnetic Resonance Imaging; Meglumine; Nausea; Organometallic Compounds; Pennsylvania; Risk Assessment; Risk Factors; Urticaria; Vomiting

2008
Tolerability and diagnostic value of gadoteric acid in the general population and in patients with risk factors: results in more than 84,000 patients.
    European journal of radiology, 2012, Volume: 81, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Comorbidity; Contrast Media; Drug-Related Side Effects and Adverse Reactions; Female; Germany; Humans; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Nausea; Organometallic Compounds; Prevalence; Risk Assessment; Risk Factors; Urticaria; Vomiting; Young Adult

2012
Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis.
    International journal of dermatology, 2012, Volume: 51, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anaphylaxis; Antiprotozoal Agents; Child; Child, Preschool; Cross-Sectional Studies; Erythema; Female; Humans; Infant; Injections, Intralesional; Iran; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Pain; Pruritus; Treatment Outcome; Vomiting; Young Adult

2012
High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients.
    The American journal of tropical medicine and hygiene, 1999, Volume: 61, Issue:5

    Topics: Adult; Amylases; Animals; Antimony; Antiprotozoal Agents; Bone Marrow; Creatinine; Female; HIV Infections; HIV-1; Humans; Leishmania infantum; Leishmaniasis, Visceral; Leukocyte Count; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Pancreatitis; Recurrence; Retrospective Studies; Vomiting

1999